Search 

RetinAI Medical is a Swiss company that supports eye care professionals and patients throughout the medical examination process using Artificial Intelligence (AI). Our vision is to foster the transition from reactive medicine to preventive medicine for high-impact diseases such as Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR) and Glaucoma. 

Our solutions rely on the latest advances in medical image analysis, ophthalmology and machine learning. We have a unique team of scientists working to fully realize the capabilities of AI, and to integrate this technology into the next generation of medical devices.

ophthalmology, machine learning, artificial intelligence, healthcare, diagnosis, support, information and technology

RiboStruct is developing the first generic treatment for genetic diseases.

RiboStruct leverages the long-term work of Marat Yusupov and Gulnara Yusupova on the crystallographic study of the eukaryotic ribosome to develop new drugs, in particular "readthrough compounds" targeting the human ribosome for the treatment of monogenic genetic diseases when they are caused by nonsense mutations (10-15% of cases).
Distinctively from gene therapies, where a specific program is needed for each disease, RiboStruct develops a pharmacological "protein repair therapy" approach, with the goal to cure multiple diseases with the same molecule by acting on a common mechanism. More than 7000 genetic diseases have been described so far, affecting altogether 300 million people worlwide.

Genetic diseases

Nonsense mutations

Premature stop codons

Readthrough

Human ribosome

Structure-based drug design

Dr Renaud Jean-Paul, President & CEO-CSO

RiboStruct is trying to achieve a first round of funding.

Aminoglycosides are known to help the ribosome overcome premature stop codons to restore the synthesis of full-length proteins but their high toxicity prevents their use on the long term as needed for the treatment of monogenic diseases caused by nonsense mutations.

RiboStruct is developing non-aminoglycoside readthrough compounds using a fragment- and structure-based drug design approach relying on an exclusive know-how on the crystallographic structure determination of the whole eukaryotic ribosome in complex with ligands and on the strong biophysical capabilities of its strategic partner NovAliX (http://www.novalix-pharma.com/).

Scailyte AG is an innovative Swiss-based company developing artificial intelligence (AI) technology for clinical research and diagnostics. We are offering a unique solution for the discovery of novel biomarkers for ultra-sensitive and early diagnosis of complex diseases such as cancer.

artificial intelligence, diagnostics, single-cell, medtech, biomarker, big data

TechsoMed is an Israeli based medical device company, developing BioTrace™, a real-time, monitoring and control system for thermal ablation procedures. The technology is applicable to multiple fields such as Oncology (tumor ablation), Cardiac (arrhythmia) and Pain management. Our breakthrough technology (based on two granted patents) is the only one which can give physicians real time monitoring and control for ablation procedures, and it can do all that by interfacing with standard ultrasound devices. The control and security we can give physicians will make our system a must-have for major ablation treatments.

cancer, immunotherapy, vaccine, telomerase

1 in 3 people will develop cancer during their lifetime, and over 90% of cancer patient deaths are caused when the cancer spreads though the body, a process called metastasis. We have identified an excellent anti-metastatic target for therapy development. Extensive pre-clinical models have shown therapeutic efficacy of targeting an enzyme called Lysyl oxidase (LOX). In addition, LOX expression is clinically correlated with metastasis and poor survival in cancer patients. Moreover, LOX is implicated in fibrosis and initial pre-clinical studies suggest LOX may also be an effective therapeutic target for limiting fibrosis. We are currently developing new antibodies against LOX that we are testing pre-clinically with the intention to move into clinical trials in human patients. Our work thus has great potential to develop new effective therapies of commercial value, and offers a real potential to impact on patient well being and survival.

TOLREMO is an ETH Spin-off founded in March 2017. The company engages in the discovery and development of small molecule drugs that target novel drug resistance pathways in cancer therapy. Despite medical advances, resistance to cancer therapies continues to limit the long-term survival of many cancer patients. The company’s innovative therapeutic approach specifically eradicates those cancer cells that ultimately cause drug resistance. Its science-based drug discovery and development pipeline is fueled by a unique screening platform for which a patent has been filed. TOLREMO’s vision is to use its personalized anti-drug resistance therapies to meaningfully prolong the lives of cancer patients.

- cancer drug resistance

- technology platform

- melanoma

- lung cancer

- pancreatic cancer

Seed Round closed in September 2017: CHF 2.4M

Torreya Partners is a leading corporate finance advisory boutique serving companies in the life sciences industry.

Founded by Tim Opler and Mark Simon, Torreya has grown to have more than 50 professionals and a global presence in life sciences advisory. We have successfully completed more than 150 assignments since we started in August 2007.

Torreya has its primary offices in London, New York and Mumbai.

Our work has taken place in pharmaceuticals, biotechnology, medical technology, diagnostics, nutritionals, pharma services and closely related sectors. Our partners are senior industry bankers and executives, with deep experience, knowledge, and networks.

We are a partner of choice for companies seeking discreet, unconflicted and knowledgeable advice on M&A, corporate finance, licensing and asset sale transactions. In some cases, Torreya Partners acts as a pure advisor on a retained basis to its clients.

Virility Medical is a clinical stage venture, engaged in the development and commercialization of treatment for premature ejaculation by method of neuromodulation. Virility’s product is an intimate perineal skin patch. The patch carries an electronic module that delivers transcutaneous neuromuscular electrical stimulation to the adjacent nerves and muscles. Thus, the muscles are electrically inhibited and, the premature initiation of the ejaculation phase is delayed for the duration of stimulation, after which the patch is disposed of.

Sex Medicine

Neuromodulation

Premature Ejaculation

Electrical Stimulation